To investigate the role of Memantine as anxiolytic in elevated plus maze test and as antidepressant in tail suspension test in Swiss albino mice

Harish G. Bagewadi, T. V. Venkatadri, B. Rajeshwari


Background: The magnitude of improvement seen with present conventional medicines for anxiety and depression remain disappointing thereby providing a scope for the study of newer drugs. In the literature, there is evidence demonstrating the modulation of N-methyl-D-aspartate (NMDA)receptors in anxiety and depression. The present study is undertaken to evaluate the antianxiety effect of memantine in elevated plus maze (EPZ) test and its antidepressant effect in tail suspension test (TST)in Swiss albino mice.

Methods: Animals were divided into six groups (n=6). First group mice were given normal saline (10 ml/kg), second group were administered lorazepam (0.5 mg/kg), third group with memantine (3 mg/kg) and fourth group with memantine plus lorazepam, fifth group was administered amitriptyline (10 mg/kg)and sixth group received memantine plus amitriptyline. All drugs were administered by intraperitoneal route daily for 7 consecutive days. Results were analyzed by one-way ANOVA followed by post-hoc Tukey’s test.

Results: Memantine treated mice showed significant increase (p<0.001)in time spent and number of entries in open arm and significant decrease in time spent and number of entries in closed arm in EPZ when compared to control group. Duration of immobility was significantly (p<0.001)reduced in animals treated with memantine when compared to the control group in TST.

Conclusions: NMDA antagonist, memantine has showed significant antianxiety effect in EPZ test and antidepressant effect in TST.


Memantine, N-methyl-D-aspartate-antagonist, Elevated plus maze test, Antianxiety, Tail suspension test, Antidepressant

Full Text:



Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19.

Tevor AJ, Way WL. Sedative and the hynotics drugs. In: Katzung BG, editors. Basic and Clinical Pharmacology. 11th Edition. San Francisco: The McGraw Hill Companies; 2009: 406-7.

Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29(2-3):85-96.

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.

Koenig AM, Thase ME. First-line pharmacotherapies for depression - What is the best choice? Pol Arch Med Wewn. 2009;119(7-8):478-86.

Simon AB, Gorman JM. Advances in the treatment of anxiety: targeting glutamate. NeuroRx. 2006;3(1):57-68.

Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185(1):1-10.

Jessa M, Nazar M, Bidzinski A, Plaznik A. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. Eur Neuropsychopharmacol. 1996;6(1):55-61.

Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM. Long-term statin use and psychological well-being. J Am Coll Cardiol. 2003;42(4):690-7.

Bagewadi HG, Nayaka SR, Venkatadri TV. Effect of memantine in experimental models of depression in swiss albino mice. J Chem Pharm Res. 2014;6(12):885-91.

Chisari M, Zorumski CF, Mennerick S. Cross talk between synaptic receptors mediates NMDA-induced suppression of inhibition. J Neurophysiol. 2012;107(9):2532-40.

Stelzer A, Shi H. Impairment of GABA-A receptor function by N-methyl-D-aspartate-mediated calcium influx in isolated CA1 pyramidal cells. Neuroscience. 1994;62(3):813-28.

Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2-3):249-58.

Sills MA, Loo PS. Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate. Mol Pharmacol. 1989;36(1):160-5.

Jang SW, Liu X, Chan CB, Weinshenker D, Hall RA, Xiao G, et al. Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol. 2009;16(6):644-56.

Mao QX, Yang TD. Amitriptyline upregulates EAAT1 and EAAT2 in neuropathic pain rats. Brain Res Bull. 2010;81(4-5):424-7.

Sernagor E, Kuhn D, Vyklicky L Jr, Mayer ML. Open channel block of NMDA receptor responses evoked by tricyclic antidepressants. Neuron. 1989;2(3):1221-7.

Pellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985;14(3):149-67.

Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl).1985;85(3):367-70.

Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav. 1996;54(1):129-41.

Griebel G. 5-hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther. 1995;66:103-48.

Fernandez Espejo E. Structure of the mouse behaviour on the elevated plus-maze test of anxiety. Behav Brain Res. 1997;86(1):105-12.

Poleszak E, Serefko A, Szopa A, Wosko S, Dudka J, Wrobel A, et al. NMDA receptor activation antagonizes the NMDA antagonist-induced antianxiety effect in the elevated plus-maze test in mice. Pharmacol Rep. 2013;65(5):1124-31.

Karve AV, Jagtiani SS, Chitnis KA. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. Indian J Pharmacol. 2013;45(3):244-7.

Patel P, Gohil KJ, Roy SP, Patel N. Investigation of antidepressant and anxiolytic activity of curcumin given alone and in combination with amitriptyline in rats. Indian J Res Pharm Biotechnol. 2014;2(3):1173-8.

Poleszak E, Szewczyk B, Kedzierska E, Wlaz P, Pilc A, Nowak G. Antidepressant and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav. 2004;78(1):7-12.

Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav. 1996;54(1):129-42.

Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004;1(1):101-10.

Lipton SA. The molecular basis of memantine action in Alzheimer’s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res. 2005;2(2):155-65.

Lipton SA, Chen HS. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. 2004;11(1):18-20.

Kotlinska J, Liljequist S. A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701,324. Psychopharmacology (Berl). 1998;135(2):175-81.

Przegalinski E, Tatarczynska E, Chojnacka-Wójcik E. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology. 2000;39(10):1858-64.

Olney JW, Wozniak DF, Farber NB. Glumate receptor dysfunction and Alzheimer’s disease. Restor Neurol Neurosci. 1998;13(1-2):75-83.

Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. 2004;5(1):11-25.

Lejeune F, Gobert A, Rivet JM, Millan MJ. Blockade of transmission at NMDA receptors facilitates the electrical and synthetic activity of ascending serotoninergic neurones. Brain Res. 1994;656(2):427-31.

Wieronska JM, Branski P, Palvcha A, Smialowska M. The effect of competitive and non-competitive NMDA receptor antagonists, ACPC and MK-801 on NPY and CRF-like immunoreactivity in the rat brain amygdala. Neuropeptides. 2001;35(5-6):219-26.

Husum H, Van Kammen D, Termeer E, Bolwig G, Mathe A. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line ‘depressed’ rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology. 2003;28(7):1292-9.